The dosage regimen of levamisole in cancer: Is it related to efficacy and safety? (Q40147880)

17 September 2017

1 reference

title

The dosage regimen of levamisole in cancer: is it related to efficacy and safety? (English)

1 reference

17 September 2017

The dosage regimen of levamisole in cancer: Is it related to efficacy and safety? (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

3 October 2023

1 reference

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

3 October 2023

W. K. Amery

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6341264

3 October 2023

B. S. Butterworth

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A6341264

3 October 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=6341264

3 October 2023

publication date

1 January 1983

1 reference

full work available at URL

17 September 2017

https://api.elsevier.com/content/article/PII:0192056183900656?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

https://api.elsevier.com/content/article/PII:0192056183900656?httpAccept=text/plain

3 October 2023

1 reference

Crossref

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

International Journal of Immunopharmacology

3 October 2023

published in

1 reference

17 September 2017

1 reference

17 September 2017

1 reference

17 September 2017

page(s)

1-9

1 reference

Levamisole and immunotherapy: some theoretic and practical considerations and their relevance to human disease

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Clozapine-induced agranulocytosis: a situation report up to August 1976.

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Levamisole and surgery in bronchial carcinoma patients: increase in deaths from cardiorespiratory failure

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Sequential chemoimmunotherapy of colorectal cancer. Evaluation of methotrexate, Baker's antifol and levamisole

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Immunokinetics of A Single Dose of Levamisole

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

A randomized study of adjuvant immunotherapy with levamisole and Corynebacterium parvum in operable non-small cell lung cancer

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Actinomycin-D, levamisole chemoimmunotherapy of refractory malignant melanoma

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Combined chemoimmunotherapy for advanced breast cancer.A comparison of BCG and levamisole

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

An overview of the current status of levamisole in the treatment of rheumatic diseases

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Agranulocytosis during treatment with chlozapine

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Use of levamisole in recurrent aphthous stomatitis

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Use of levamisole in parasitic infections

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Immunochemotherapy of gastric cancer with levamisole

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Prognosis of primarily treated localized laryngeal carcinoma ameliorated through levamisole treatment: a randomized pilot study

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Levamisole in squamous cell carcinoma of the head and neck

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

BCG plus levamisole following irradiation of advanced squamous bronchial carcinoma

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Effect of Levamisole on E-Rosette-Forming Cells in Vivo and in Vitro in Hodgkin's Disease

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Use of levamisole in viral infections

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Use of levamisole in cancer patients

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

Adjuvant immunotherapy by levamisole in resectable lung cancer: a control study

3 October 2023

1 reference

https://api.crossref.org/works/10.1016/0192-0561(83)90065-6

3 October 2023

Identifiers

1 reference

17 September 2017

1 reference